Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

194.30 +0.22 (+0.11%)
Streaming Delayed Price Updated: 9:43 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Ascendis (ASND) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Earnings Scheduled For August 7, 2025
 
Via Benzinga
What's Driving the Market Sentiment Around Ascendis Pharma?
 
Via Benzinga
What's Driving the Market Sentiment Around Ascendis Pharma?
 
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
 
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
 
Via Benzinga
Is Ascendis Pharma Gaining or Losing Market Support?
 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
 
Via Benzinga
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
A Glimpse of Ascendis Pharma's Earnings Potential
 
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
 
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
 
Via Benzinga
Earnings Scheduled For February 12, 2025
 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
 
Via Benzinga
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing? 
Via Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock?
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
Looking Into Ascendis Pharma's Recent Short Interest
 
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
 
Via Benzinga
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock?
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
Looking Into Ascendis Pharma's Recent Short Interest
 
Via Benzinga
Why Is BioMarin Stock Trading Higher On Thursday?
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results. 
Via Benzinga
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.